Overview

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:
0

Participant gender:
All

Summary

This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate
Tofacitinib

Criteria

Inclusion Criteria:

- Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate
who have inadequate response to Tumor Necrosis Factor (TNF) inhibitors.

Exclusion Criteria:

- Pregnancy, severe acute or chronic medical conditions, including serious infections or
clinically significant laboratory abnormalities.